Optimizing Dosing Strategies in Oral Iron Supplementation
Launched by LUZERNER KANTONSSPITAL · Feb 1, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how different ways of taking iron supplements can help people with iron deficiency and anemia. Specifically, researchers want to find out if taking a higher dose of iron every other day is more effective than taking a standard dose every day. They will measure how well each method works by looking at changes in hemoglobin levels, which is a protein in red blood cells that carries oxygen, after 12 weeks of treatment.
To participate, individuals must be at least 18 years old and have low ferritin levels (a sign of iron deficiency), along with some other health criteria. The study involves three visits over 12 weeks, where participants will receive either the higher dose every other day or the standard dose every day. This trial is currently looking for new participants, and it offers a chance to contribute to understanding better ways to treat iron deficiency.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Informed Consent signed by the subject
- • ≥18 years of age
- • Iron deficiency: Ferritin \<30 µg/l
- • hemoglobin ≥ 80 g/l
- • CRP \< 5 mg/l
- Exclusion Criteria:
- • Refusal of study participation,
- • Regular administration of Erythropoietin
- • Oral or intravenous iron supplementation \<12 weeks prior to investigation
- • Contraindications to intervention medication (Tardyferon), e.g. known hypersensitivity or allergy to iron sulfate / ferrous sulfate
- • Blood transfusion or donation \<12 weeks prior to investigation
- • Active chemotherapy
- • Inability to follow the procedures of the investigation, e.g. due to language problems, psychological disorders, dementia, etc. of the subject.
- • Note
- Due to slow recruitment, the following inclusion criterion was removed on 09/25/2024 (MM/DD/YYYY):
- • Anemia (as defined by the WHO): Hemoglobin \<130 g/L for men, Hemoglobin \<120 g/l for women, Hemoglobin \<110 g/l for pregnant women
About Luzerner Kantonsspital
Luzerner Kantonsspital (LUKS) is a leading academic hospital located in Lucerne, Switzerland, dedicated to providing high-quality healthcare and advancing medical research. As a prominent clinical trial sponsor, LUKS is committed to fostering innovation in medical treatments and therapies through rigorous clinical studies. The institution emphasizes collaboration with multidisciplinary teams of healthcare professionals, researchers, and academic partners to ensure that its trials adhere to the highest ethical standards and regulatory requirements. With a focus on improving patient outcomes, LUKS leverages its state-of-the-art facilities and expertise to contribute significantly to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Luzern, , Switzerland
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported